Curious about today's AI digest?ai-tldr.dev
Pomegra LogoPomegra

Daily Digest

BriefMarket · bearishMedium impact
Esc

Telix Pharmaceuticals Stock Falls 3% After $1.65B ITM Acquisition

Telix Pharmaceuticals2 min read6 sources

Why is Telix Pharmaceuticals stock down today?

Telix Pharmaceuticals (TLX.AX) stock fell 3% to A$17.31 on Monday after the Australian company agreed to buy Germany's ITM Isotope Technologies for $1.65B, issuing shares equal to 23.7% of the enlarged group.

Key numbers

Upfront deal price$1.65B+$700M potential milestones = $2.35B total
ITM-11 milestone structure$700M$250M on FDA approvals; $450M if 2030 sales exceed $150M
Combined 2026E revenue (pro forma)>$1.3Bvs $803.8M Telix standalone in 2025
Telix 2025 revenue$803.8M+56% vs 2024 (per [3])
TLX.AX on announcement dayA$17.31-3.03% [4]
New shares issued (ITM holders' stake)105.8M shares23.7% of enlarged company at US$11.84/share

What happened

Telix Pharmaceuticals (TLX.AX) stock fell 3% to A$17.31 on Monday after the Australian company agreed to buy Germany's ITM Isotope Technologies for $1.65B, issuing shares equal to 23.7% of the enlarged group. The deal pairs Telix's growing cancer drug pipeline with ITM's factories producing lutetium-177 (177Lu) — the radioactive ingredient at the heart of several FDA-approved cancer treatments — and ITM is the only company in the world making 177Lu at commercial grade and scale. The combined group is projected to generate over $1.3B in revenue in 2026, compared with Telix's standalone $803.8M in 2025, which was already 56% higher than the prior year. ITM's lead drug, ITM-11, targets a rare stomach-and-pancreas cancer called GEP-NETs but was rejected by the FDA in August 2026 for manufacturing deficiencies; the merger gives Telix the manufacturing expertise to refile.

Why it matters

Telix Pharmaceuticals is positioning itself to challenge Novartis — the dominant force in cancer radiotherapy, with its Pluvicto and Lutathera drugs generating nearly $2.8B in combined 2025 sales — by owning its own supply of the scarce radioactive ingredients those drugs require. The global radioligand therapy market is forecast to grow from about $3.2B today to $30B by 2034, and companies with secure in-house access to 177Lu, 225Ac, and 161Tb will have a structural edge over rivals that must source these isotopes from outside. ITM-11, if it clears the FDA's manufacturing concerns and wins approval, would compete directly with Novartis's Lutathera for GEP-NET patients.

Who this affects

Marketbearish
Medium impact
Dilution from 105.8M new shares weighs on TLX.AX near term.
Companymixed
High impact
Telix gains isotope supply control; shareholders diluted 23.7%.
Competitorsbearish
Medium impact
Novartis faces a better-resourced radiopharma challenger in GEP-NETs.
Industrybullish
High impact
Radiopharma supply consolidation accelerates; 177Lu access tightens for rivals.

Telix Pharmaceuticals vs Novartis, Lantheus

Telix PharmaceuticalsTLX:ASXA$5.7B-4.2%+16%$803.8M
NovartisNVS:NYSE$268.5B+0.2%+1.9%$2.8B (RLT)
Lantheus (acq. pending)LNTH:NASDAQ$6.5B-0.3%—$1.54B

As of 2026-09-23

How we got here

  1. FDA rejects ITM-11 NDA for manufacturing deficiencies

  2. Telix announces $1.65B ITM acquisition; TLX.AX falls 3%

  3. Telix shareholder vote on ITM deal expected

  4. Target close for Telix–ITM merger, pending regulatory approvals

What to watch

  • Telix shareholder vote; institutional pushback on 23.7% dilution could derail deal.2026-11
  • ITM-11 NDA resubmission after FDA's August manufacturing rejection.Q4 2026
  • COMPOSE Phase 3 interim data for ITM-11 in Grade 2–3 GEP-NETs.H1 2027

Educational content only. Not investment advice.

More briefsAll briefs →